Scientists dig into tissue samples to unravel lung scarring mystery
NCT ID NCT00084305
First seen Jun 27, 2026 · Last updated Sep 17, 2026 · Updated 13 times
Summary
This study collects and analyzes blood, DNA, and tissue samples from 315 adults with pulmonary fibrosis, their relatives, and healthy volunteers. The goal is to learn more about the disease's causes, not to test a new treatment. Researchers hope the findings will guide future therapies.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- What this could lead to
- If successful, this research could reveal new clues about what causes pulmonary fibrosis, potentially pointing toward future treatments.
- What could go wrong
- This is an observational study, not a treatment trial. It may not directly lead to new therapies, and results may take years to translate into clinical practice.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
315 people
The number who actually took part.
- Started
-
Jun 2004
- Lead sponsor
-
A government research agency
The lead sponsor is the US National Institutes of Health.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Patients with pulmonary fibrosis@@@@@@
- Ages
-
18 to 115 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
* INCLUSION CRITERIA: Individuals who are 18 years of age or older with any of the following: * Idiopathic pulmonary fibrosis \[defined by the American Thoracic Society/European Respiratory Society guidelines\], * Familial pulmonary fibrosis \[defined as idiopathic pulmonary fibrosis in two or more first-degree relatives\], * Relatives of patients with hereditary pulmonary fibrosis, * Hermansky-Pudlak syndrome (diagnosed by paucity or deficiency of platelet dense bodies on whole mount electron microscopy or by genetic testing), * Pulmonary fibrosis associated with collagen vascular diseases or autoinflammatory disorders, * Pulmonary fibrosis post-COVID-19 \[i.e., pulmonary fibrosis in an individual recovering from SARS-CoV-2 infection\], or * Healthy research volunteers by history and indicated tests (individuals without history of chronic pulmonary disorder, collagen vascular disease, or bleeding disorder). EXCLUSION CRITERIA: Individuals with any of the following: * Significant inhalational exposure to fibrogenic fibers or dusts or exposure to drugs associated with pulmonary fibrosis, * Uncontrolled ischemic heart disease, * Uncorrectable bleeding diathesis, * Pregnancy or lactation (excluded due to exposure of unnecessary risks), or * Inability to give informed consent (excluded due to exposure of unnecessary risks).
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Healthy volunteers are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
National Institutes of Health Clinical Center
Bethesda, Maryland, 20892, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New sedative candidate goes Head-to-Head with propofol in early human test
- Can Device-Preserved donor lungs boost transplant success?
- Can a Room-Temperature dairy drink build muscle?
- New injection MWN117 tested for safety in obesity
- Patients and families build a living database of pulmonary fibrosis
- Can a new drug avoid the high? soticlestat put to the test